This Article Abstract Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Aljada, A. Articles by Dandona, P. Search for Related Content PubMed PubMed Citation Articles by Aljada, A. Articles by Dandona, P.

Insulin Inhibits the Expression of Intercellular Adhesion Molecule-1 by Human Aortic Endothelial Cells through Stimulation of Nitric Oxide¹

Division of Endocrinology, Diabetes, and Metabolism, State University of New York, Buffalo, New York 14209; and Kaleida Health, Buffalo, New York 14209

Address all correspondence and requests for reprints to: Paresh Dandona, M.D., Ph.D., Diabetes-Endocrinology Center of Western New York, State University of New York, 3 Gates Circle, Buffalo, New York 14209. E-mail: pdandona{at}mfhs.edu

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
Intercellular adhesion molecule-1 (ICAM-1) is expressed by endothelial and other cell types and participates in inflammation and atherosclerosis. It serves as a ligand for leukocyte function-associated antigen-1 on leukocytes and is partially responsible for the adhesion of lymphocytes, granulocytes, and monocytes to cytokine-stimulated endothelial cells and the subsequent transendothelial migration. Its expression on endothelial cells is increased in inflammation and atherosclerosis. As it has been suggested that insulin and hyperinsulinemia may have a role in atherogenesis, we have now investigated whether insulin has an effect on the expression of ICAM-1 on human aortic endothelial cells (HAEC). HAEC were prepared from human aortas by collagenase digestion and were grown in culture. Insulin (100 and 1000 µU/mL) caused a decrease in the expression of ICAM-1 (messenger ribonucleic acid and protein) by these cells in a dose-dependent manner after incubation for 2 days. This decrease was associated with a concomitant increase in endothelial nitric oxide synthase (NOS) expression also induced by insulin. To examine whether the insulin-induced inhibition of ICAM-1 was mediated by nitric oxide (NO) from increased endothelial NOS, HAEC were treated with N-nitro-L-arginine, a NOS inhibitor. N-Nitro-L-arginine inhibited the insulin-induced decrease in ICAM-1 expression in HAEC at the messenger ribonucleic acid and protein levels. Thus, the inhibitory effect of insulin on ICAM-1 expression is mediated by NO. We conclude that insulin reduces the expression of the proinflammatory adhesion molecule ICAM-1 through an increase in the expression of NOS and NO generation and that insulin may have a potential antiinflammatory and antiatherosclerotic effect rather than a proatherosclerotic effect.

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
THE ASSOCIATION of hyperinsulinemia with increased coronary events in several epidemiological studies led to the hypothesis that insulin may be atherogenic (1, 2, 3). However, the epidemiological association of hyperinsulinemia with atherosclerosis has several shortcomings. Firstly, it does not establish a causal relationship between hyperinsulinemia and atherosclerosis. Secondly, this association has not been established for women in various studies. It is possible that although insulin resistance contributes to the pathogenesis of atherosclerosis, the role of hyperinsulinemia needs further investigation in this regard.

It has recently been shown that insulin is an arterial and venous vasodilator (4, 5, 6, 7). It stimulates the release of nitric oxide (NO) from human umbilical endothelial cells (8), and we have also demonstrated that insulin increases the expression of endothelial nitric oxide synthase (e-NOS) by human aortic endothelial cells (HAEC) (9), the enzyme that synthesizes NO (10). The acute release of NO induced by insulin and the increase in e-NOS expression over a longer period are consistent with the vasodilatory effect of insulin. As NO is believed to be antiatherogenic (11, 12, 13), and its inhibitor, N^G-monomethyl-L-arginine (L-NMMA), may be proatherogenic in experimental animals (14), it is likely that insulin may also have an antiatherogenic role. If so, it may reduce the expression of intercellular adhesion molecule-1 (ICAM-1), the adhesion molecule whose plasma concentrations have been shown to be related to future coronary heart disease events (15, 16, 17). ICAM-1 is constitutively expressed by endothelial cells, and its expression increases during inflammation and after endotoxin challenge (18, 19, 20).

In view of the above, we have investigated this concept further to examine the possibility that insulin may inhibit the expression of ICAM-1 in endothelial cells. Leukocyte function-associated antigen-1, the ligand of ICAM-1, is found in circulating monocytes. The binding of this ligand to ICAM-1 on endothelial cells allows monocytes to adhere to these cells, leading to the initiation of the atherogenic process on the endothelial surface (21, 22, 23). Thus, the expression of ICAM-1 on the endothelial surface may be an important determinant of potential atherogenicity in a patient. This report describes the inhibitory effect of insulin on ICAM-1 expression in HAEC through a NO pathway-mediated mechanism.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
Cell isolation and harvesting

Human endothelial cells were harvested from human aortas and arterial vessels by the method described by Gospodarowicz et al. (24). The vessels were washed several times with phosphate-buffered saline (PBS) and incubated with 0.1% collagenase/dispase solution (Roche Molecular Biochemicals, Indianapolis, IN) in medium 199 (Life Technologies, Inc., Grand Island, NY) for 20 min. The solution was spun, and the cells were collected and harvested in flasks coated with FBS. The identity of the cells was confirmed by immunohistochemical staining, which was positive for factor VIII, Ulex europaeous, EN4, CD31, and negative for -actin. All experiments were performed using cultures at a passage of 5–6. HAEC were allowed to reach 90% confluence and then cells were washed with PBS and taken to endothelial cell growth medium (Clonetics, Walkersville, MD) containing 2% charcoal/dextran-stripped FBS (HyClone Laboratories, Inc., Logan, UT) for 24 h. On the second day, the cells were induced with insulin (0, 100, and 1000 µU/mL) and incubated for 2 days with or without N-nitro-L-arginine (L-NNA; Sigma-Aldrich Corp., St. Louis, MO).

Western blotting

Total cell lysates were prepared by washing the adherent cells with PBS followed by 1 mL boiling lysis buffer (1% SDS, 1 mmol/L sodium orthovanadate, and 10 mmol/L Tris, pH 7.4). Cells were scraped and transferred to a microcentrifuge tube, boiled for an additional 5 min, and centrifuged at 14,000 x g for 5 min. Total protein concentrations were determined using bicinchoninic acid protein assay (Pierce Chemical Co., Rockford, IL). Twenty micrograms of total cell lysate were electrophoresed on 6% SDS-polyacrylamide gels. Proteins were transferred to polyvinylidene difluoride membrane. The membrane was blocked for 1 h in 5% nonfat dry milk in 0.02% Tween/Tris-buffered saline buffer and then incubated overnight with a monoclonal antibody against e-NOS (Transduction Laboratories, Inc., Lexington, KY). The membrane was washed four times for 15 min each time with 0.02% Tween/Tris-buffered saline buffer and then incubated with peroxidase-conjugated goat antimouse Ig for 1 h. Finally, the membrane was washed and developed using supersignal chemiluminescence reagent (Pierce Chemical Co.).

ICAM-1 RT-PCR

Total ribonucleic acid (RNA) was extracted from HAEC by a single step guanidium thiocyanate-phenol-chloroform extraction method. Total RNA was treated with deoxyribonuclease I (50 U). Complementary DNA was synthesized by RT using a RETROscript first strand synthesis kit for RT-PCR (Ambion, Inc., Austin, TX). Takara human ß-actin competitive PCR (Takara, Inc., Japan) was used to correct the RNA amount for PCR among the samples. Quantum RNA 18S internal standard (Ambion, Inc., Austin, TX) or 40S ribosomal RNA S9 was used in the relative PCR as housekeeping genes. PCR primers for ICAM-1 were purchased from CLONTECH Laboratories, Inc. (Palo Alto, CA). PCR was performed in a final volume of 25 µL by adding 17.65 µL deionized H₂O, 2.5 µL 10 x PCR buffer, 1.25 µL deoxy-NTP (2.5 mmol/L), 1 µL ICAM-1 primers, 2.5 µL complementary DNA, and 0.1 µL SuperTaq polymerase (Ambion, Inc.). Two-stage thermal cycling was performed (94 C for 30 s, 68 C for 2 min). The optimal number of cycles for ICAM-1 was determined, and PCR reactions were then run under denaturing conditions on 5% polyacrylamide/8 mol/L urea ready-made gels (Bio-Rad Laboratories, Inc., Hercules, CA). Gels were then fixed and stained with silver staining using Bio-Rad Laboratories, Inc., Silver Staining Plus kit.

ICAM-1 protein levels

ICAM-1 protein levels were measured by an enzyme-linked immunosorbent assay kit obtained from R&D Systems, Inc. (Minneapolis, MN). Samples were homogenized in 0.5 mL homogenization buffer [10 mmol/L Tris-HCl (pH 7.4), 1 mmol/L ethylenediamine tetraacetate, 0.05% sodium azide, 1% Tween-80, 150 mmol/L NaCl, 2 mmol/L phenylmethylsulfonylfluoride, 1 µg/mL leupeptin, 1 µg/mL pepstatin A, and 1 µg/mL aprotinin] and analyzed according to kit procedure.

Statistical analysis

Statistical analysis was carried out using SigmaStat software (Jandel Scientific, San Rafael, CA). Paired t test was used to compare the levels of e-NOS and ICAM-1 in HAEC control cells (0 µU/mL insulin) vs. those in insulin-induced HAEC (100 and 1000 µU/mL insulin with or without L-NNA).

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
HAEC homogenates from cells induced with 0, 100, and 1000 µU/mL insulin showed a dose-dependent increase in e-NOS after incubation with insulin for 2 days, as measured by Western blotting (Fig. 1, A and B). ICAM-1 gene expression as measured by RT-PCR was inhibited by insulin significantly after incubation for 2 days (Fig. 2). The concentration at which insulin inhibited ICAM-1 on the messenger RNA (mRNA) level was 100 µU/mL in some experiments and 1000 µU/mL in others. The histogram, based on densitometric readings, shows the means of four experiments, indicating that the inhibition was dose dependent, with a threshold at 100 µU/mL (Fig. 3). Treatment of HAEC with L-NNA inhibited the inhibitory effect of insulin on ICAM-1 gene expression (Fig. 3, A and B). This indicates that the inhibitory effect of insulin on ICAM-1 gene expression is mediated through the NO pathway. L-NNA did not alter basal ICAM-1 expression in HAEC in the absence of insulin.

View larger version (34K): [in this window] [in a new window]   Figure 1. A, A representative Western blot showing the induction of e-NOS in HAEC by insulin. Cells were induced with 0, 100, and 1000 µU/mL insulin for 2 days (P < 0.05). EC is the HAEC positive control for e-NOS (PharMingen/Transduction Laboratories, San Diego, CA). B, Densitometric quantitation of e-NOS expression in HAEC.

View larger version (50K): [in this window] [in a new window]   Figure 2. A, RT-PCR of ICAM-1 using 28 cycles. ICAM-1 was amplified using specific primers that produce a PCR product of 379 bp. 18S ribosomal RNA PCR products have a size of 488. The graph shows two sets of experiments. B, Densitometry of ICAM-1 RT-PCR.

View larger version (36K): [in this window] [in a new window]   Figure 3. A, RT-PCR of ICAM-1. 40S ribosomal RNA S9 was used as a housekeeping gene. It was amplified using specific primers that give a PCR product of 430 bp. L-NNA (0.25 mmol/L) was used to inhibit insulin inhibitory effect (P < 0.05). Results show clearly that ICAM-1 mRNA levels are inhibited by insulin, and the addition of L-NNA reverted ICAM-1 mRNA levels to baseline levels. HAEC were incubated with insulin and L-NNA for 2 days. B, Percent change in mRNA levels of ICAM-1, as measured by densitometry.

View larger version (36K): [in this window] [in a new window]   Figure 4. ICAM-1 protein levels 0.25 mmol/L L-NNA and 0.5 mmol/L L-NNA were used to inhibit the insulin inhibitory effect on ICAM-1 protein levels. Cells were incubated with L-NNA and insulin for 2 days.

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

ICAM-1 is an adhesion molecule of the Ig family and is expressed on the endothelial cell surface. Its ligand, leukocyte function-associated antigen-1, which is expressed on the monocyte membrane, allows the monocyte to adhere to the endothelial cell surface to initiate the inflammatory and atherogenic processes. Increased expression of ICAM-1 is induced by endotoxin in vitro and in vivo (25, 26); an increase in ICAM-1 on the endothelial cell surface is also induced by tumor necrosis factor- (TNF) (27). ICAM-1 is a marker for inflammation and atherosclerosis; its increased levels have been shown to predict coronary events (15, 16, 17). Thus, ICAM-1 is both a mediator of inflammation and atherosclerosis as well as a marker for atherosclerosis-related clinical events.

The inhibitory effect of insulin on ICAM-1 expression allied with its potent vasodilatory effect (4, 5, 6, 7) and antiplatelet effect (28) are potentially antiatherogenic. Furthermore, some of these effects appear to be mediated through NO release. NO, too, is considered antiatherogenic (12, 13, 14), and its inhibition by L-NNA leads to a proinflammatory and proatherogenic state in the vessel wall (14). These observations support the concept that insulin is probably an unlikely mediator of atherosclerosis in insulin-resistant states. We have to look for another mediator of atherosclerosis in insulin resistance states; TNF may be one such putative molecule, as it is increased in insulin-resistant states (29, 30) and may actually antagonize insulin action at the adipocyte (31) and endothelial cell (32) levels. Indeed, TNF has been shown to increase ICAM-1 expression and to decrease NOS expression in HAEC (27, 33). TNF is also an established mediator of the acute inflammation that follows endotoxin injection (34).

In conclusion, insulin inhibits the expression of ICAM-1 markedly in HAEC. This inhibition is probably mediated by increased NO release and NOS expression, as it is inhibited by a NOS inhibitor. This effect of insulin is suggestive of an antiinflammatory action of this hormone. This effect of insulin along with its vasodilatory and antiplatelet effects militate against a proatherogenic role for insulin.

	Footnotes

 
¹ Supported by The William G. McGowan Charitable Fund, Inc.

Received February 9, 2000.

Revised March 30, 2000.

Accepted April 1, 2000.

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 

1. Standl E. 1995 Hyperinsulinemia and atherosclerosis. Clin Invest Med. 18:261–266.[Medline]
2. Kekalainen P, Sarlund H, Farin P, Kaukanen E, Yang X, Laakso M. 1996 Femoral atherosclerosis in middle-aged subjects: association with cardiovascular risk factors and insulin resistance. Am J Epidemiol. 144:742–748.[Abstract/Free Full Text]
3. Festa A, D’Agostino Jr R, Mykkanen L, et al. 1999 Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS). Arterioscler Thromb Vasc Biol. 19:562–568.
4. Baron AD, Brechtel G, Johnson A, Fineberg N, Henry DP, Steinberg HO. 1994 Interactions between insulin and norepinephrine on blood pressure and insulin sensitivity. Studies in lean and obese men. J Clin Invest. 93:2453–2462.
5. Scherrer U, Randin D, Vollenweider P, Vollenweider L, Nicod P. 1994 Nitric oxide release accounts for insulin’s vascular effect in humans. J Clin Invest. 94:2511–2515.
6. Chaudhuri A, Kanjwal Y, Mohanty P, Rao S, Sung BH, Wilson M, Dandona P. 1999 Insulin induced vasodilatation of internal carotid artery. Metabolism. 48:1–5.[CrossRef][Medline]
7. Grover A, Padginton C, Wilson MF, Sung BH, Izzo Jr JL, Dandona P. 1995 Insulin attenuates norepinephrine-induced venoconstriction. An ultrasonographic study. Hypertension. 25:779–784.[Abstract/Free Full Text]
8. Zeng G, Quon MJ. 1996 Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. J Clin Invest. 98:894–898.[Medline]
9. Aljada A, Dandona P. 2000 Effect of insulin on human aortic endothelial nitric oxide synthase. Metabolism. 49:147–150.[CrossRef][Medline]
10. Palmer RM, Moncada S. 1989 A novel citrulline-forming enzyme implicated in the formation of nitric oxide by vascular endothelial cells. Biochem Biophys Res Commun. 158:348–352.[CrossRef][Medline]
11. Cartwright JE, Whitley GS, Johnstone AP. 1997 Endothelial cell adhesion molecule expression and lymphocyte adhesion to endothelial cells: effect of nitric oxide. Exp Cell Res. 235:431–434.[CrossRef][Medline]
12. Brune B, Hanstein K. 1998 Rapid reversibility of nitric oxide induced platelet inhibition. Thromb Res. 90:83–91.[CrossRef][Medline]
13. Riddell DR, Owen JS. 1999 Nitric oxide and platelet aggregation. Vitam Horm. 57:25–48.[Medline]
14. Luvara G, Pueyo ME, Philippe M, et al. 1998 Chronic blockade of NO synthase activity induces a proinflammatory phenotype in the arterial wall: prevention by angiotensin II antagonism. Arterioscler Thromb Vasc Biol. 18:1408–1416.
15. Shyu KG, Chang H, Lin CC, Kuan P. 1996 Circulating intercellular adhesion molecule-1 and E-selectin in patients with acute coronary syndrome. Chest. 109:1627–1630.[Abstract/Free Full Text]
16. Wallen NH, Held C, Rehnqvist N, Hjemdahl P. 1999 Elevated serum intercellular adhesion molecule-1 and vascular adhesion molecule-1 among patients with stable angina pectoris who suffer cardiovascular death or non-fatal myocardial infarction. Eur Heart J. 20:1039–1043.[Abstract/Free Full Text]
17. Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J. 1998 Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet. 351:88–92.[CrossRef][Medline]
18. Van de Stolpe A, van der Saag PT. 1996 Intercellular adhesion molecule-1. J Mol Med. 74:13–33.[Medline]
19. Watanabe T, Fan J. 1998 Atherosclerosis and inflammation mononuclear cell recruitment and adhesion molecules with reference to the implication of ICAM-1/LFA-1 pathway in atherogenesis. Int J Cardiol. 66(Suppl 1):S45–S53.
20. Nakae H, Endo S, Inada K, Takakuwa T, Kasai T. 1996 Changes in adhesion molecule levels in sepsis. Res Commun Mol Pathol Pharmacol. 91:329–338.[Medline]
21. Marlin SD, Springer TA. 1987 Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1). Cell. 51:813–819.[CrossRef][Medline]
22. Luscinskas FW, Cybulsky MI, Kiely JM, Peckins CS, Davis VM, Gimbrone Jr MA. 1991 Cytokine-activated human endothelial monolayers support enhanced neutrophil transmigration via a mechanism involving both endothelial-leukocyte adhesion molecule-1 and intercellular adhesion molecule-1. J Immunol. 146:1617–1625.[Abstract]
23. Davis CAd, Pearce WH, Haines GK, Shah M, Koch AE. 1993 Increased ICAM-1 expression in aortic disease. J Vasc Surg. 18:875–880.[CrossRef][Medline]
24. Gospodarowicz D, Moran J, Braun D, Birdwell C. 1976 Clonal growth of bovine vascular endothelial cells: fibroblast growth factor as a survival agent. Proc Natl Acad Sci USA. 73:4120–4124.[Abstract/Free Full Text]
25. Amberger A, Maczek C, Jurgens G, et al. 1997 Co-expression of ICAM-1, VCAM-1, ELAM-1 and Hsp60 in human arterial and venous endothelial cells in response to cytokines and oxidized low-density lipoproteins. Cell Stress Chaperones. 2:94–103.[CrossRef][Medline]
26. Panes J, Perry MA, Anderson DC, et al. 1995 Regional differences in constitutive and induced ICAM-1 expression in vivo. Am J Physiol. 269:H1955–H1964.
27. Haraldsen G, Kvale D, Lien B, Farstad IN, Brandtzaeg P. 1996 Cytokine-regulated expression of E-selectin, intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1) in human microvascular endothelial cells. J Immunol. 156:2558–2565.[Abstract]
28. Trovati M, Massucco P, Mattiello L, Mularoni E, Cavalot F, Anfossi G. 1994 Insulin increases guanosine-3',5'-cyclic monophosphate in human platelets. A mechanism involved in the insulin anti-aggregating effect. Diabetes. 43:1015–1019.[Abstract]
29. Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB. 1995 The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest. 95:2111–2119.
30. Dandona P, Weinstock R, Thusu K, Abdel-Rahman E, Aljada A, Wadden T. 1998 Tumor necrosis factor- in sera of obese patients: fall with weight loss. J Clin Endocrinol Metab. 83:2907–2910.[Abstract/Free Full Text]
31. Hotamisligil GS, Shargill NS, Spiegelman BM. 1993 Adipose expression of tumor necrosis factor-: direct role in obesity-linked insulin resistance. Science. 259:87–91.[Abstract/Free Full Text]
32. Aljada A, Ghanim H, Assian E, Dansona P. 1999 Tumor necrosis factor- inhibits insulin induced nitric oxide synthase and insulin receptor autophosphorylation in human aortic endothelial cells [Abstract]. Diabetes. 48(Suppl):A32.
33. Mohamed F, Monge JC, Gordon A, Cernacek P, Blais D, Stewart DJ. 1995 Lack of role for nitric oxide (NO) in the selective destabilization of endothelial NO synthase mRNA by tumor necrosis factor-. Arterioscler Thromb Vasc Biol. 15:52–57.[Abstract/Free Full Text]
34. Tracey KJ, Fong Y, Desse D, et al. 1987 Anticachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia. Nature 330:662–664.

This article has been cited by other articles:

				M. T. McCormick, K. W. Muir, C. S. Gray, and M. R. Walters Management of Hyperglycemia in Acute Stroke: How, When, and for Whom? Stroke, July 1, 2008; 39(7): 2177 - 2185. [Full Text] [PDF]

				S. Dickinson, D. P Hancock, P. Petocz, A. Ceriello, and J. Brand-Miller High-glycemic index carbohydrate increases nuclear factor-{kappa}B activation in mononuclear cells of young, lean healthy subjects Am. J. Clinical Nutrition, May 1, 2008; 87(5): 1188 - 1193. [Abstract] [Full Text] [PDF]

				S. Walrand, C. Guillet, Y. Boirie, and M.-P. Vasson Insulin Differentially Regulates Monocyte and Polymorphonuclear Neutrophil Functions in Healthy Young and Elderly Humans J. Clin. Endocrinol. Metab., July 1, 2006; 91(7): 2738 - 2748. [Abstract] [Full Text] [PDF]

				R. Garg, A. Chaudhuri, F. Munschauer, and P. Dandona Hyperglycemia, Insulin, and Acute Ischemic Stroke: A Mechanistic Justification for a Trial of Insulin Infusion Therapy Stroke, January 1, 2006; 37(1): 267 - 273. [Abstract] [Full Text] [PDF]

				M. Wehling-Henricks, M. C. Jordan, K. P. Roos, B. Deng, and J. G. Tidball Cardiomyopathy in dystrophin-deficient hearts is prevented by expression of a neuronal nitric oxide synthase transgene in the myocardium Hum. Mol. Genet., July 15, 2005; 14(14): 1921 - 1933. [Abstract] [Full Text] [PDF]

				T. J. Stalker, Y. Gong, and R. Scalia The Calcium-Dependent Protease Calpain Causes Endothelial Dysfunction in Type 2 Diabetes Diabetes, April 1, 2005; 54(4): 1132 - 1140. [Abstract] [Full Text] [PDF]

				M. O. Goodarzi, K. D. Taylor, X. Guo, M. J. Quinones, J. Cui, X. Li, T. Hang, H. Yang, E. Holmes, W. A. Hsueh, et al. Variation in the Gene for Muscle-Specific AMP Deaminase Is Associated With Insulin Clearance, a Highly Heritable Trait Diabetes, April 1, 2005; 54(4): 1222 - 1227. [Abstract] [Full Text] [PDF]

				S. R. Kashyap, L. J. Roman, J. Lamont, B. S. S. Masters, M. Bajaj, S. Suraamornkul, R. Belfort, R. Berria, D. L. Kellogg Jr., Y. Liu, et al. Insulin Resistance Is Associated with Impaired Nitric Oxide Synthase Activity in Skeletal Muscle of Type 2 Diabetic Subjects J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 1100 - 1105. [Abstract] [Full Text] [PDF]

				J. G. Tidball Inflammatory processes in muscle injury and repair Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2005; 288(2): R345 - R353. [Abstract] [Full Text] [PDF]

				K. M. Choi, K. W. Lee, S. G. Kim, N. H. Kim, C. G. Park, H. S. Seo, D. J. Oh, D. S. Choi, and S. H. Baik Inflammation, Insulin Resistance, and Glucose Intolerance in Acute Myocardial Infarction Patients without a Previous Diagnosis of Diabetes Mellitus J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 175 - 180. [Abstract] [Full Text] [PDF]

				A. Aljada, P. Mohanty, H. Ghanim, T. Abdo, D. Tripathy, A. Chaudhuri, and P. Dandona Increase in intranuclear nuclear factor {kappa}B and decrease in inhibitor {kappa}B in mononuclear cells after a mixed meal: evidence for a proinflammatory effect Am. J. Clinical Nutrition, April 1, 2004; 79(4): 682 - 690. [Abstract] [Full Text] [PDF]

				R. Rossi, G. Origliani, and M. G. Modena Transdermal 17-{beta}-Estradiol and Risk of Developing Type 2 Diabetes in a Population of Healthy, Nonobese Postmenopausal Women Diabetes Care, March 1, 2004; 27(3): 645 - 649. [Abstract] [Full Text] [PDF]

				S. K. Andersen, J. Gjedsted, C. Christiansen, and E. Tonnesen The roles of insulin and hyperglycemia in sepsis pathogenesis J. Leukoc. Biol., March 1, 2004; 75(3): 413 - 421. [Abstract] [Full Text] [PDF]

				S. Clement, S. S. Braithwaite, M. F. Magee, A. Ahmann, E. P. Smith, R. G. Schafer, and I. B. Hirsch Management of Diabetes and Hyperglycemia in Hospitals Diabetes Care, February 1, 2004; 27(2): 553 - 591. [Full Text] [PDF]

				P. Dandona, A. Aljada, P. Mohanty, H. Ghanim, A. Bandyopadhyay, and A. Chaudhuri Insulin Suppresses Plasma Concentration of Vascular Endothelial Growth Factor and Matrix Metalloproteinase-9 Diabetes Care, December 1, 2003; 26(12): 3310 - 3314. [Abstract] [Full Text] [PDF]

				J. S. Steingrub, P. E. Marik, and G. P. Zaloga Steroids and Drotrecogin Alfa (Activated) for Severe Sepsis Chest, November 1, 2003; 124(5): 2033 - 2034. [Full Text] [PDF]

				P. Dandona, A. Aljada, A. Chaudhuri, and A. Bandyopadhyay The Potential Influence of Inflammation and Insulin Resistance on the Pathogenesis and Treatment of Atherosclerosis-Related Complications in Type 2 Diabetes J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2422 - 2429. [Full Text] [PDF]

				P. Dandona, A. Aljada, and A. Bandyopadhyay The Potential Therapeutic Role of Insulin in Acute Myocardial Infarction in Patients Admitted to Intensive Care and in Those With Unspecified Hyperglycemia Diabetes Care, February 1, 2003; 26(2): 516 - 519. [Full Text] [PDF]

				Z. He, C. Rask-Madsen, and G.L. King Mechanisms of cardiovascular complications in diabetes and potential new pharmacological therapies Eur. Heart J. Suppl., January 1, 2003; 5(suppl_B): B51 - B57. [Abstract] [PDF]

				M. Federici, R. Menghini, A. Mauriello, M. L. Hribal, F. Ferrelli, D. Lauro, P. Sbraccia, L. G. Spagnoli, G. Sesti, and R. Lauro Insulin-Dependent Activation of Endothelial Nitric Oxide Synthase Is Impaired by O-Linked Glycosylation Modification of Signaling Proteins in Human Coronary Endothelial Cells Circulation, July 23, 2002; 106(4): 466 - 472. [Abstract] [Full Text] [PDF]

				J. E. Da Silva-Santos, M. C. Santos-Silva, F. d. Q. Cunha, and J. Assreuy The Role of ATP-Sensitive Potassium Channels in Neutrophil Migration and Plasma Exudation J. Pharmacol. Exp. Ther., March 1, 2002; 300(3): 946 - 951. [Abstract] [Full Text] [PDF]

				B. M. Matata and M. Galinanes Effect of Diabetes on Nitric Oxide Metabolism During Cardiac Surgery Diabetes, November 1, 2001; 50(11): 2603 - 2610. [Abstract] [Full Text] [PDF]

				A. Aljada, R. Garg, H. Ghanim, P. Mohanty, W. Hamouda, E. Assian, and P. Dandona Nuclear Factor-{{kappa}}B Suppressive and Inhibitor-{{kappa}}B Stimulatory Effects of Troglitazone in Obese Patients with Type 2 Diabetes: Evidence of an Antiinflammatory Action? J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 3250 - 3256. [Abstract] [Full Text] [PDF]

				P. Dandona, A. Aljada, P. Mohanty, H. Ghanim, W. Hamouda, E. Assian, and S. Ahmad Insulin Inhibits Intranuclear Nuclear Factor {{kappa}}B and Stimulates I{{kappa}}B in Mononuclear Cells in Obese Subjects: Evidence for an Anti-inflammatory Effect? J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 3257 - 3265. [Abstract] [Full Text] [PDF]

				M. Montagnani, I. Golovchenko, I. Kim, G. Y. Koh, M. L. Goalstone, A. N. Mundhekar, M. Johansen, D. F. Kucik, M. J. Quon, and B. Draznin Inhibition of Phosphatidylinositol 3-Kinase Enhances Mitogenic Actions of Insulin in Endothelial Cells J. Biol. Chem., January 11, 2002; 277(3): 1794 - 1799. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Aljada, A. Articles by Dandona, P. Search for Related Content PubMed PubMed Citation Articles by Aljada, A. Articles by Dandona, P.